Analysis-Investors see big Novo Nordisk stock boost if obesity drug shows heart benefit
By Maggie Fick LONDON (Reuters) – Positive trial data showing Novo Nordisk’s obesity drug helps save and extend lives, not just lose weight, could propel Europe’s best-performing stock even higher, according to 10 investors and industry analysts interviewed by Reuters. Demand for the Danish company’s weight-loss treatment Wegovy is soaring in the United States, leading…
